SCHEMBL4757985

SCHEMBL4757985

Nc1nc2c(cnn2CCOCc2ccccc2)c2nc(-c3ccco3)nn12

nearest known ligand 0.77

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.77
ADORA1 P30542 6/20 0.77
KDM4E B2RXH2 1/20 0.77
NPC1 O15118 1/20 0.77
ALDH1A1 P00352 1/20 0.77
TP53 P04637 1/20 0.77
CYP3A4 P08684 1/20 0.77
ADORA3 P0DMS8 1/20 0.77
HPGD P15428 1/20 0.77
ALOX15 P16050 1/20 0.77
MAPK1 P28482 1/20 0.77
ADORA2B P29275 1/20 0.77
RAB9A P51151 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
HSD17B10 Q99714 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sch-58261 SCHEMBL537287 0.87 ADORA2A (1.00) ADORA2AADORA1KDM4ENPC1ALDH1A1
Sch-63390 SCHEMBL5823548 0.85 ADORA2A (1.00) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL21833054 0.85 ADORA2A (0.71) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL7345461 0.85 ADORA2A (1.00) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL12972222 0.83 ADORA2A (0.77) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL4759580 0.82 ADORA2A (0.76) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL13904673 0.82 ADORA2A (0.76) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL13853059 0.82 ADORA2A (0.76) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL21832255 0.81 ADORA2A (0.75) ADORA2AADORA1KDM4ENPC1ALDH1A1
SCHEMBL7339226 0.81 ADORA2A (1.00) ADORA2AADORA1KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470698-B2 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-12-30 US disclosed
US-20070249641-A1 ADENOSINE A3 RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2007-10-25 US disclosed
US-7271171-B2 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2007-09-18 US disclosed
US-20060040959-A1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-02-23 US disclosed
US-6921825-B2 Adenosine A3 receptor modulators KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) 2005-07-26 US disclosed
US-20030144266-A1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-07-31 US disclosed
US-6448253-B1 Adenosine A3 receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2002-09-10 US disclosed
US-6407236-B1 TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS MEDCO RESEARCH, INC. 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040959-A1 Adenosine A3 receptor modulators ADORA3, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885KDM4E 4280/4885
US-20070249641-A1 ADENOSINE A3 RECEPTOR MODULATORS ADORA3, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885KDM4E 4280/4885
US-20030144266-A1 Adenosine A3 receptor modulators ADORA3, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.